dc.contributor.author
Van der Auwera, G.
dc.contributor.author
Bart, A.
dc.contributor.author
Chicharro, C.
dc.contributor.author
Cortes, S.
dc.contributor.author
Di Muccio, T.
dc.contributor.author
Dujardin, J.
dc.contributor.author
Felger, I.
dc.contributor.author
Paglia, M. G.
dc.contributor.author
Grimm, F.
dc.contributor.author
Harms, G. [u.v.m.]
dc.date.accessioned
2018-06-08T10:26:20Z
dc.date.available
2017-02-02T12:24:32.784Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/20446
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-23749
dc.description.abstract
Leishmaniasis is a vector-borne disease which is endemic in 98 countries
worldwide [1]. It is caused by protozoan parasites of the genus Leishmania,
which are transmitted by female sand flies of the genera Lutzomyia and
Phlebotomus. Many infected individuals never develop symptoms, but those who
do can exhibit various disease manifestations [2]. Visceral leishmaniasis (VL)
or kala-azar is the severe form, whereby parasites infect internal organs and
the bone marrow, a lethal condition if left untreated. Other disease types are
restricted to the skin (cutaneous leishmaniasis, CL) or the mucosae of the
nose and mouth (mucosal leishmaniasis, ML). Finally, a particular cutaneous
disease sometimes develops in cured VL patients: post kala-azar dermal
leishmaniasis (PKDL). Typically, VL is caused by two species: Leishmania
donovani and Leishmania infantum. The latter can also cause CL, as can all
other pathogenic species. Some particular species (e.g. L. braziliensis and L.
aethiopica) can lead to overt ML. As many as 20 different Leishmania species
are able to infect humans, and globally there are over 1 million new disease
cases per annum [1,3]. Leishmaniasis is endemic in southern Europe, and in
other European countries cases are diagnosed in travellers who have visited
affected areas both within the continent and beyond. Although treatment in
practice is often guided only by clinical presentation and patient history, in
some cases determination of the aetiological subgenus, species complex or
species is recommended for providing optimal treatment [2,4,5]. For example, a
patient returning from South America with CL might be infected with Leishmania
braziliensis, which necessitates systemic drug therapy and counselling about
the risk of developing mucosal leishmaniasis in the future. The same patient
could also be infected with Leishmania mexicana, which is managed by less
intensive treatment and which is not associated with mucosal disease [6].
Determining the infecting species and its probable source permits selection of
the correct drug, route of administration (intralesional, oral systemic, or
parenteral) and duration [7]. Unfortunately, for CL it is impossible to
predict the species responsible for an ulcerating lesion clinically, and the
morphology of amastigotes does not differ between species. When the
geographical origin of infection is known, for instance when a patient in an
endemic region is treated at a local hospital, the species can be guessed
often from the known local epidemiology, as species distribution follows a
geographical pattern [8]. However, especially in infectious disease clinics
that treat patients who have stayed in various endemic countries, the
geographic origin of infections may be unknown. For instance, people residing
in Europe who have travelled outside Europe may come from, or have also
visited, Leishmania-endemic areas within Europe, especially the Mediterranean
basin. Even when the location of infection is known, several species can co-
circulate in a given endemic area, in which case the species can only be
determined by laboratory tests. Culture and subsequent isoenzyme analysis is
time consuming and available in very few specialised centres, so it is
impractical as a front-line diagnostic test in clinical laboratories. Hence,
well-performed reliable molecular methods are necessary for species
identification. Several Leishmania typing methods have been published
(reviewed in [9]), and as a result each laboratory uses its own preferred
assay. The most popular assays nowadays are those that can be applied directly
to clinical samples, thereby circumventing the need for parasite isolation and
culture. However, few tests have been standardised, and no commercial kits are
currently available. As a result, clinical and epidemiological studies make
use of various techniques, and in patient management other methods are often
deployed. In this study we compare the typing performance in 16 clinical
laboratories across Europe, which use a variety of methods for species
discrimination.
en
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Comparison of Leishmania typing results obtained from 16 European clinical
laboratories in 2014
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
Eurosurveillance. - 21 (2016), 49, Artikel Nr. 2
dcterms.bibliographicCitation.doi
10.2807/1560-7917.ES.2016.21.49.30418
dcterms.bibliographicCitation.url
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22662
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000026247
refubium.note.author
Der Artikel wurde in einer reinen Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000007615
dcterms.accessRights.openaire
open access